更新M6未知位置妊娠风险预测模型并评估临床因素
本研究前瞻性队列纳入5473例未知位置妊娠(PUL),分两阶段在八家单位招募,更新M6模型并评估加入临床因素能否提升性能。重新拟合的M6P模型在内部-外部交叉验证中AUC为0.89、敏感性94%,时间外部验证AUC为0.84-0.88、敏感性92-93%。加入临床因素后部分中心性能改善,尤其孕酮不适用或不可及时。
要点
- 更新M6模型对异位妊娠诊断性能准确,敏感性优异。
- 加入临床因素后部分中心性能改善。
- 孕酮不适用或不可及时加入临床因素更有价值。
核心结论
- 更新M6模型提供准确的诊断性能,对异位妊娠敏感性优异。
- 加入临床因素后部分中心性能改善,尤其孕酮水平不适用或不可及时。
研究设计与样本
- 前瞻性队列研究,2015年1月至2017年1月在八家单位连续招募PUL(第一阶段),两家中心2017年1月至2021年3月继续招募(第二阶段)。
- 共招募5473例PUL,排除母亲年龄<16岁或初始β-hCG≤25 IU/L者709例,最终4764例(87%)纳入分析(第一阶段2894例,第二阶段1870例)。
- 常规采集血清检测β-hCG和孕酮,记录母亲年龄、疼痛评分、出血评分和异位妊娠史。
- 随访中根据经阴道超声和/或生化确认将PUL分类为失败PUL、宫内妊娠或异位妊娠(包括持续性PUL)。
- 重新拟合含孕酮(M6P)和不含孕酮(M6NP)的M6模型并扩展临床因素,采用内部-外部交叉验证(第一阶段)和时间外部验证(第二阶段),缺失值用多重插补处理。
主要发现
- 重新拟合的M6P模型对异位妊娠/持续性PUL vs 宫内妊娠/失败PUL的AUC:IECV为0.89,EV为0.84-0.88;敏感性分别为94%和92-93%。
- 重新拟合的M6NP模型AUC:IECV为0.85,EV为0.82-0.86;敏感性分别为92%和93-94%。
- 校准性能总体良好,但中心间存在异质性;净获益确认临床效用。
- M6P扩展加入母亲年龄、出血评分和异位妊娠史后,AUC变化因中心和阶段不同在-0.02至0.01之间。
- M6NP扩展后AUC变化在-0.01至0.03之间;在5%阈值定义高风险时,扩展M6P使敏感性变化-0.02至-0.01、特异性变化0.03至0.04、净获益变化-0.005至0.006;扩展M6NP使敏感性变化-0.03至-0.01、特异性变化0.05至0.07、净获益变化-0.005至0.006。
关键数值与推荐
- M6P模型:IECV的AUC 0.89,敏感性94%;EV的AUC 0.84-0.88,敏感性92-93%。
- M6NP模型:IECV的AUC 0.85,敏感性92%;EV的AUC 0.82-0.86,敏感性93-94%。
- 5%阈值定义异位妊娠/持续性PUL高风险。
临床怎么用
- 更新M6模型可用于PUL风险分层,对异位妊娠敏感性优异。
- 在部分中心加入临床因素可改善模型性能,尤其孕酮不适用或不可及时。
局限性
- 校准性能总体良好但中心间存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Ectopic pregnancy (EP) is a major high-risk outcome following a pregnancy of unknown location (PUL) classification. Biochemical markers are used to triage PUL as high vs low risk to guide appropriate follow-up. The M6 model is currently the best risk-prediction model. We aimed to update the M6 model and evaluate whether performance can be improved by including clinical factors. METHODS: This prospective cohort study recruited consecutive PUL between January 2015 and January 2017 at eight units (Phase 1), with two centers continuing recruitment between January 2017 and March 2021 (Phase 2). Serum samples were collected routinely and sent for β-human chorionic gonadotropin (β-hCG) and progesterone measurement. Clinical factors recorded were maternal age, pain score, bleeding score and history of EP. Based on transvaginal ultrasonography and/or biochemical confirmation during follow-up, PUL were classified subsequently as failed PUL (FPUL), intrauterine pregnancy (IUP) or EP (including persistent PUL (PPUL)). The M6 models with (M6P ) and without (M6NP ) progesterone were refitted and extended with clinical factors. Model validation was performed using internal-external cross-validation (IECV) (Phase 1) and temporal external validation (EV) (Phase 2). Missing values were handled using multiple imputation. RESULTS: Overall, 5473 PUL were recruited over both phases. A total of 709 PUL were excluded because maternal age was < 16 years or initial β-hCG was ≤ 25 IU/L, leaving 4764 (87%) PUL for analysis (2894 in Phase 1 and 1870 in Phase 2). For the refitted M6P model, the area under the receiver-operating-characteristics curve (AUC) for EP/PPUL vs IUP/FPUL was 0.89 for IECV and 0.84-0.88 for EV, with respective sensitivities of 94% and 92-93%. For the refitted M6NP model, the AUCs were 0.85 for IECV and 0.82-0.86 for EV, with respective sensitivities of 92% and 93-94%. Calibration performance was good overall, but with heterogeneity between centers. Net Benefit confirmed clinical utility. The change in AUC when M6P was extended to include maternal age, bleeding score and history of EP was between -0.02 and 0.01, depending on center and phase. The corresponding change in AUC when M6NP was extended was between -0.01 and 0.03. At the 5% threshold to define high risk of EP/PPUL, extending M6P altered sensitivity by -0.02 to -0.01, specificity by 0.03 to 0.04 and Net Benefit by -0.005 to 0.006. Extending M6NP altered sensitivity by -0.03 to -0.01, specificity by 0.05 to 0.07 and Net Benefit by -0.005 to 0.006. CONCLUSIONS: The updated M6 model offers accurate diagnostic performance, with excellent sensitivity for EP. Adding clinical factors to the model improved performance in some centers, especially when progesterone levels were not suitable or unavailable. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Kyriacou C, Ledger A, Bobdiwala S, et al. Updating M6 pregnancy of unknown location risk-prediction model including evaluation of clinical factors. Ultrasound Obstet Gynecol. 2024. PMID: 37842861. doi:10.1002/uog.27515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。